C D317, also referred to as BST-2, HM1.24, or tetherin, is a lipid raft-associated type II transmembrane glycoprotein that localizes to the cell surface and various intracellular membranes (1, 2) . Expression of CD317 in cultured cells restricts the release of a diverse spectrum of enveloped viruses, including the human pathogens HIV, Lassa virus, and Kaposi's sarcoma-associated herpesvirus (KSHV) (3) (4) (5) . In cell lines, the inhibitory virological effect induced by CD317 expression is rather striking, yet the relevance of CD317 for the control of virus infections in vivo is unclear.
CD317's capacity to form virion-restraining "tethers" likely underlies its ability to bridge virion and cellular membranes via its N-and C-terminal membrane-anchoring domains and to organize into parallel disulfide-bond homodimers (6) (7) (8) . This current model of virus restriction implies that expression of CD317 in target cells of productive infection is a prerequisite for its ability to interfere with virus replication. However, the pattern and regulation of CD317 expression in the human host, particularly on cells that are susceptible to productive infection, remain poorly defined.
Based on its apparently selective expression on the surface of terminally differentiated B cells (9) , CD317 has been proposed as a therapeutic target for multiple myeloma and related plasma cell-derived immunoproliferative disorders (9-13). Antibodybased pharmacodelivery approaches are particularly interesting for treatment of chemotherapy-resistant malignancies (14) , and the cytotoxicity of anti-CD317 mAbs has been demonstrated in multiple myeloma xenotransplant models (10, 15) . Based on these results, the European Medicines Agency's Committee for Orphan Medicinal Products issued a positive opinion for the use of a humanized anti-HM1.24/CD317 mAb for the treatment of multiple myeloma. More recently, antibody-based immunotherapy strategies have been proposed for various solid human tumors with high-level CD317 expression (16) (17) (18) (19) (20) .
In the present work, we characterized the in vivo expression profile of CD317 in nontransformed tissues to provide a framework for studies of its biological functions in humans, with a focus on its potential importance as an antiviral factor and on therapeutic strategies proposing CD317 as a target for immunotherapy of B-cell malignancies and solid tumors.
Results

CD317 Is Expressed on Specialized Cells in a Variety of Human Tissues.
As a methodological basis for a comprehensive evaluation of CD317 expression in vivo, we developed an immunohistochemical staining protocol for formalin-fixed, paraffin-embedded tissue sections, given that standard protocols yielded only low-level staining in tonsil ( Fig. S1 and SI Results). The mouse anti-HM1.24 mAb, specific for an epitope in the extracellular domain of CD317 (15) , was used as primary detection reagent. The specificity and sensitivity of this immunohistochemical staining protocol was validated on patient-derived multiple myeloma (9), tonsil tissue, and human cell lines expressing high endogenous CD317 levels (21) or no CD317 (3) (SI Results and Figs. S2 and S3A).
In a cross-sectional CD317 expression analysis, we used a tissue microarray (TMA) containing 468 individual sections derived from 25 paraffinized nontransformed tissue samples from more than 210 patients. CD317 expression was rated based on a combined proportion and intensity scoring system reported by Allred et al (22) . Remarkably, CD317 was expressed in more than 40% of patient samples in 21 of the tissues analyzed (Figs. 1 and 2A and Fig. S4 ). The expression scores varied considerably among tissues; the highest scores were seen in spleen, gallbladder, and stomach (>70% medium or high expression scores), whereas more moderate expression scores were seen in pancreas, adrenal gland, small intestine, liver, and salivary gland (40-70% medium or high expression scores) (Fig. 2B ). More than half of the cases analyzed for heart, ovary, uterus, kidney, testis, and bladder tissues received low or medium scores. CD317 expression in lung, appendix, skin, tonsil, fat, and thyroid samples of the TMA was low or negative (Figs. 1 and 2B and Fig. S4 ). In a complementary approach, Western blot analyses of snap-frozen samples of tissues with high (liver, gallbladder, spleen) or low (thyroid) CD317 expression on immunohistochemistry (Figs. 1 and 2) were confirmatory (Fig. S3B) .
Based on histological criteria, CD317 expression in organ sections of the TMA was identified on type I and type II pneumocytes in the lung, intercalated and striated ducts of major salivary glands, squamous epithelium of the esophagus, gastric fundic epithelium and glands, Paneth cells of the small intestine, mononuclear cells in the lamina propria of the large intestine, acinar cells of the exocrine pancreas, hepatocytes, gallbladder epithelium, cells in the adrenal zona reticularis, collecting ducts of the kidney, Leydig cells in the testis, endometrial glands, and vasculature ( Fig. 1 and Fig. S4 ). Thus, in contrast to previous work (9), we found CD317 to be widely expressed and exposed on a number of specialized cell types.
CD317 Is Ubiquitously Expressed on Blood Vessels. We next focused on the CD317 expression on vasculature. Blood vessels in all tissues represented in the TMA demonstrated CD317 staining in the lumen-oriented endothelial lining. In highly vascularized organs, such as spleen, the majority of CD317 expression was on blood vessels ( Fig. 1 and Fig. S5A ), but prominent vessel staining was observed in sections from gastrointestinal tract, muscular tissue of the heart (Fig. 3A) , liver, pancreas, and bladder as well (Fig. S5A ). In line with these immunohistological findings, CD317 expression colocalized with expression of the blood vessel endothelial cell marker CD31 (platelet endothelial cell adhesion molecule, PECAM-1) in the endothelium of larger arteries such as coronary arteries and the aorta, as well as in smaller, organassociated blood vessels such as those found in tonsil ( Fig. 3B and Fig. S5B ). We conclude that CD317 is highly expressed on blood vessels throughout the body. + monocytes were the only cell type in peripheral blood that expressed high levels of CD317 (Fig. 4C ).
An initial expression analysis in a previous study (23) indicated preferential expression of CD317 on cell lines with characteristics of bone marrow stroma; based on this, the surface protein was termed bone marrow stromal antigen 2 (BST-2). In the present study, we assessed CD317 expression in bone marrow aspirates from healthy donors. A considerable fraction of nucleated bone marrow cells stained positive for CD317 by immunohistochemistry (Fig. 4D, Left) . In Ficoll gradient-purified bone marrow, the majority of cells that expressed the stromal cell marker CD106 (VCAM-1) (24) coexpressed CD317 on the surface (Fig. 4D) . Furthermore, colabeling analyses of the lamina propria of the large intestine with cell type-specific markers identified CD138 + plasma cells, but not HIV target cells (i.e., CD4 T cells, macrophages, dendritic cells), as the major CD317 + cell type (Fig. S6 ). These findings indicate that, along with terminally differentiated B cells (9) , monocytes and primary bone marrow stromal cells express high levels of CD317 within the hematopoietic lineage. 
Expression of CD317 on Human Plasmacytoid Dendritic Cells Is Not
Constitutive. In mice, CD317 is a constitutively expressed surface antigen on plasmacytoid dendritic cells (pDCs) (25) and a frequently used marker for positive selection of pDCs from lymphatic organs. In human tonsil, BDCA2 + pDCs were found predominantly in the T-cell-rich lymphocyte wall and to a lesser extent in the perifollicular region (Fig. S7A, Left) . Coexpression analysis of CD317 and BDCA2 by in situ immunofluorescence microscopy ( Fig. S7A , Right) and flow cytometry (Fig. S7B) found no evidence of significant CD317 expression on pDCs from human tonsil. Similarly, CD317 was not expressed on BDCA2 + pDCs from Ficoll gradient-purified PBMCs, in line with a recent report (26) . In isolated pDCs, stimulation with type I IFNs upregulated CD317 mRNA levels by twofold to fivefold (Fig. S7C ) and CD317 surface levels by threefold to fivefold (Fig. S7D) .
Collectively, these results demonstrate a species-specific expression pattern of CD317 on pDCs. In contrast to mice, CD317 is not constitutively expressed on pDCs in human blood and tonsil, but can be up-regulated by type I IFNs, at least on isolated cells.
Type I IFNs May Only Partially Regulate CD317 Expression In Vivo. On various types of cultured cells, CD317 is up-regulated after exposure to type I IFNs (4, 27) , consistent with its function as an antiviral restriction factor and the presence of IFN-response elements in the CD317 promoter (28) . We examined the degree to which the prominent CD317 expression in certain cell types and tissues in vivo was induced by IFN. We began by performing colabeling studies with the myxomavirus resistance protein A (MxA). The expression of MxA, which restricts the replication of orthomyxoviruses and other RNA viruses (29) , is strictly dependent on stimulation by type I or type III IFNs, classifying MxA as a convenient marker for IFN bioactivity (30) . Individual expression analyses of each restriction factor showed that the majority of MxA-expressing cells in tonsil were located within germinal centers, with additional cells staining positive in the lymphocyte wall and perifollicular region (Fig. 5A) . In contrast, the majority of CD317 + cells were found in the perifollicular region, and few cells within germinal centers expressed CD317. Most importantly, double-immunofluorescence microscopy demonstrated that cells in tonsil typically expressed either MxA or CD317 (Fig. 5A, Lower and Fig. S8A ), and that coexpression was a rare event ( factors was found on vessel endothelium, as exemplified in aorta samples from several patients (Fig. 5B, Right and Fig. S8C ).
To explore whether exogenous IFN stimulation can trigger CD317 expression in tonsil explants, we exposed dispersed human lymphoid aggregate cultures (tonsil-HLAC; ref. 31) to IFN-α for 24 h. This ex vivo stimulation enhanced CD317 expression on tonsillar lymphocytes only marginally, whereas a strong and concentration-dependent increase of MxA expression was seen (Fig. S9A) . As a reference, IFN-α also readily triggered surface expression of CD317 on Jurkat-TAg cells (Fig. S9B) .
Collectively, these results suggest a cell type-and/or tissuerelated IFN dependence of CD317 expression. Whereas marked CD317-MxA coexpression was found in vessel endothelium, their nearly mutually exclusive expression pattern in lymphoid and pulmonary tissue and insensitivity to exogenous IFN stimulation suggest that type I IFNs may only partially regulate CD317 levels in vivo.
Discussion
Our in vivo expression profiling of the antiviral restriction factor and potential tumor-targeting antigen CD317 in nontransformed human organs documented widespread tissue expression on a number of specialized cell types. This stands in contrast to a previous report suggesting selective expression of CD317 on the surface of nontransformed, terminally differentiated B cells (9) . Explicitly, that earlier study described a lack of CD317 expression on PBMCs, lymph nodes, liver, spleen, kidney, and heart, applying the identical anti-HM1.24 mAb. Although we can confirm CD317 expression on plasma cells, our study identified many additional CD317 + cell types and tissues throughout the body, greatly expanding the expression profile of this protein. We suspect that differences in the sensitivity of immunodetection might underlie this discrepancy. Our findings refute the widely held belief that the constitutive expression of CD317 in humans is highly restricted, a misperception that has spurred antibodybased immunotherapy strategies for multiple myeloma and certain solid human tumors (9) (10) (11) (12) (13) (16) (17) (18) (19) (20) . In line with our findings, a previous Northern blot analysis documented CD317 mRNA in several tissues, including pancreas, liver, lung, and heart (23).
The role of CD317 in the control of virus replication in vivo is not completely understood; however, several lines of evidence point to an important antiviral capacity of CD317 in mammals. First, various completely unrelated viruses (i.e., lentiviruses, herpes viruses, filoviruses, orthomyxoviruses) encode CD317 antagonists with distinct modes of action to overcome the restriction imposed by CD317 (5). Second, anti-CD317 activities have evolved in three different lentiviral genes (nef, env, and vpu) (32), implying a critical role of CD317 in the lentivirus-host adaption and cross-species transmission. In support of this notion, a nef-deleted simian immunodeficiency virus rapidly acquired compensatory changes in gp41 in infected rhesus macaques that restored resistance to CD317/tetherin (33) . Third, CD317 proteins from different species show evidence of positive selection, consistent with adaptations in response to invading viruses (32) . The present study establishes that CD317 is expressed on a variety of specialized cell types known to be in vivo targets for enveloped viruses. For example, vascular endothelial cells, identified as high CD317 expressors, are major replication sites of hemorrhagic fever viruses (e.g., Lassa virus, Ebola virus, Hantaan virus), as well as KSHV, vesicular stomatitis virus, and herpes simplex virus (34) . In the lung, CD317
+ type I and II alveolar pneumocytes are targeted by various respiratory pathogens, including influenza viruses (35) , severe acute respiratory syndrome coronavirus (36) , and respiratory syncytial virus (37) . Remarkably, cell culture experiments have already demonstrated that CD317 can exert antiviral activity against some of these pathogens, including Lassa virus, vesicular stomatitis virus, influenza A virus, Ebola virus, and KSHV (5, 38) . Intriguingly, the latter three viruses encode CD317 antagonists, indicating evolutionary adaptation of these pathogens. In addition, hepatocytes, monocytes, epithelial cells, terminally differentiated B cells, and bone marrow stromal cells, which express CD317 in vivo, are sites of replication for diverse viruses. The insights provided by the current expression profiling underscore CD317's in vivo relevance as an antiviral factor and suggest the possibility of future studies to investigate whether some of these other viruses are affected by this restriction factor and/or have evolved antagonists.
Although HIV encodes potent CD317 antagonists, namely Vpu and Env, where the virus actually encounters CD317 in vivo remains unclear. In secondary lymphoid organs and gut epithelium, major cell types for productive infection (i.e., CD4 T cells, macrophages, dendritic cells, and pDCs) did not express significant levels of CD317. Although the subset of CD16 + monocytes might serve as an HIV-1 reservoir (39), it seems unlikely that this minor population of infected, CD317
+ cells exerts sufficient selection pressure for HIV to preserve CD317 antagonistic activities. It is conceivable that systemic responses in HIV-infected individuals enhance CD317 expression in CD4 T cells, or that susceptible cells in other anatomic compartments, such as genitial mucosa, show a different profile of constitutive expression and regulation. In support of the former notion, a previous study found that CD4 T cells in blood and lymph nodes from African green monkeys and rhesus macaques rapidly up-regulated CD317 mRNA after simian immunodeficiency virus infection (40) .
Secretion of type I IFNs from virus-infected cells is a hallmark of antiviral immunity. Potential target cells of infection that receive these signals increase expression of IFN-stimulated genes, many of which are linked to antiviral functions (41) (42) (43) . The IFN responsiveness of CD317 in cultured primary cells is subtle; monocyte-derived macrophages up-regulated CD317 mRNA levels by less than twofold (44) , and protein levels were elevated only slightly (27) . Moreover, in the present study, type I IFN stimulation increased CD317 levels on isolated pDCs only moderately, and CD317 expression on lymphocytes in tonsil was largely unresponsive to IFN. In line with the latter observation, virtually no coexpression of CD317 and the strictly IFN-induced restriction factor MxA was observed in tonsillar and pulmonary tissue. In contrast, the abundant MxA-CD317 coexpression in vascular endothelial cells is consistent with an IFN-mediated costimulation. Taken together, these findings suggest that type I IFNs may be a key regulator of CD317 expression only in certain cell types and tissues. Conceivably, other cytokines (e.g., TNF-α, IL-1, IL-6) secreted by the host in response to a viral insult may possibly trigger CD317 expression in vivo (28) .
Along with antiviral activity, other functions of CD317 are starting to emerge for which knowledge of CD317's in vivo expression profile is of interest, including its proposed capacity as a negative trans regulator of pDC responses (26) and as an organizer of the subapical actin cytoskeleton in polarized epithelial cells (45) . In support of the relevance of the latter function, gallbladder epithelial cells, which express high levels of CD317 in situ ( Figs. 1 and 2) , are characterized by a particularly pronounced structural polarization (46) . From a therapeutic perspective, the widespread expression of human CD317, in particular its presence on a number of vital cell types, calls into question the proposed development of tumor-selective, CD317-based targeting strategies.
Materials and Methods
Paraffinized Tissues. All paraffinized tissue specimens were provided by the tissue bank of the National Center for Tumor Diseases (Heidelberg, Germany) and approved by Heidelberg University's Ethics Committee (approval no. 206/ 2005). For the systematic expression analysis of CD317, an in-house TMA containing a total of 468 paraffinized tissue sections from 25 different healthy organs was used. After immunohistochemical staining for CD317, TMA slides were scanned for image acquisition using the Aperio ScanScope CS, analyzed with Aperio ImageScope software, and rated in principle based on the immunoreactive scoring system of Allred et al. (22) . Each section was assigned two scores, one score for the portion of cells that stained positive (0, <1% positive cells; 1, 1-10% positive cells; 2, 11-33% positive cells; 3, 34-66% positive cells; 4, >66% positive cells), and another score for the intensity of staining (0, no staining; 1, weak staining; 2, intermediate staining; 3, strong staining) The overall amount of CD317 was then calculated as the sum of the scores for the portion of positive, tissue-specific cells and staining intensity. A total score of 7 was categorized as high staining, scores of 5 and 6 as medium staining, and scores of 2-4 as low staining (Fig. 2B) .
Immunoenzyme Staining. The primary and secondary antibodies used are listed in Tables S1 and S2 . Isotype-and concentration-matched mouse control mAbs and/or preimmune rabbit Ig served as negative controls. Immunoenzyme stainings of CD317 were performed on 2-μm paraffin sections of formalin-fixed tissues using standard avidin-biotin anti-alkaline phosphatase techniques (Vectastain; Vector Laboratories). Antigen retrieval was achieved by steam-cooking the slides in 10 mM citrate buffer (pH 6.1; Dako) for 30 min. A solution of 10% Earle's balanced salt solution (EBSS, SigmaAldrich) supplemented with 1% Hepes, 0.2% BSA, and 0.1% saponin (all from Sigma-Aldrich), pH 7.4, was used as a washing and permeabilization buffer. Primary Ab dilutions also were prepared in this buffer with 4% γ-venin (Behring) added and incubated overnight at 4°C. Biotinylated sheep anti-mouse IgG was applied as a secondary reagent for 30 min at room temperature. Naphthol AS-biphosphate (Sigma-Aldrich) with New Fuchsin (Merck) was used as the substrate for alkaline phosphatase. Slides were viewed with an Olympus BX45 microscope.
Additional information, including procedures for double-immunofluorescence staining, purification of pDCs and PBMCs, HLAC from tonsil, IFN-α stimulation, immunoblotting, CD317 mRNA analysis, flow cytometry, confocal microscopy, and details on the TMA, is provided in SI Materials and Methods.
